Since anti-CTLA-4 and anti-PD-1 employ distinct biological pathways to restimulate lymphocytic functions, various therapeutic strategies have combined them to extract synergistic anti-tumor effects, leading to superior clinical outcomes compared to monotherapies [37,51]. This evidence concerns the gene PDCD1 and neoplasm.